Category Archives: R&D

Margaret Hamburg Addresses Biopharma’s Pressing Issues

Speaking at the 2014 New York BIO conference, FDA Commissioner, Dr. Margaret Hamburg, addressed the pressing issues affecting the biopharmaceutical industry and the FDA. Applied Clinical Trials’ Moe Alsumidaie relays Dr Hamburg’s the highlights of Dr. Hamburg’s presentation below.
Also posted in FDA, Regulatory | Tagged , , , , , | 1 Comment

Ukraine: Still Open for Clinical Trials

By Lisa Henderson, Applied Clinical Trials. The recent geopolitical developments in Ukraine have seriously influenced the conditions and the environment for clinical trials in Ukraine and in Russia. In a webinar today, Natalia Fetkovska, Senior Partner at SanaClis, a CRO providing clinical trial services for Central and Eastern Europe (CEE), highlighted the problems.
Also posted in Europe, Global | Tagged , , , | Leave a comment

Lilly Increases Access to Clinical Trials Data

Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. The website, which houses data from several clinical trial sponsors, was created with support from PhRMA and EFPIA to increase access to and transparency of clinical trial results for researchers around the world.  
Also posted in E-Media, multimedia, Regulatory, Safety, Technology | Tagged , | Leave a comment

BRIC Nations' "Blossoming Healthcare Budgets" Revive Clinical Trials Opportunities

While some clinical trial sponsors have been driven out of the BRIC nations, a rise in rank for each country — Brazil, Russia, India, China — is expected over the next four years, indicating “blossoming healthcare budgets and markets that are ripe with opportunities for development”. According to a Thomson Reuters report, Overcoming Clinical Challenges in BRIC […]
Also posted in Emerging Markets, Europe, Global | Tagged , , , | Leave a comment

Turkey to See Renewed Multinational Investment, Says Report

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide. Although the Turkish government’s price referencing system and fixed euro-lira conversion rate have presented a major obstacle for pharma growth, the report states that these pricing challenges […]
Also posted in Emerging Markets, Europe, Global, Manufacturing, pricing | Tagged , , | Leave a comment
  • Categories

  • Meta